#soul machine - if we had a couple of similar ‘high brand’ clients (wow like Pfizer) then 2c a bargain.
unfortunately we do not - having high level well recognised customers equals validation of the product.
creeping revenues may sustain the company and its workforce but larger clients and tangible revenues will sustain shareholders. Nothing less relegates us to ongoing speculation.
The periodic takeover talk IMHO is way too premature. GLTAH 2024
UNITH SOFT LAUNCH of the PLATFORM......BIGGER THINGS to come in 2024, page-47
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
